JP2021098733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021098733A5 JP2021098733A5 JP2021037490A JP2021037490A JP2021098733A5 JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5 JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021037490 A JP2021037490 A JP 2021037490A JP 2021098733 A5 JP2021098733 A5 JP 2021098733A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 116
- 239000000427 antigen Substances 0.000 claims 53
- 102000036639 antigens Human genes 0.000 claims 53
- 108091007433 antigens Proteins 0.000 claims 53
- 102000004169 proteins and genes Human genes 0.000 claims 36
- 108090000623 proteins and genes Proteins 0.000 claims 36
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 25
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 25
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 25
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 25
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 12
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 12
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 12
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 9
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims 4
- 101710148283 Choline transporter-like protein 4 Proteins 0.000 claims 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 claims 3
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- LJPIRKICOISLKN-WHFBIAKZSA-N Gly-Ala-Ser Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O LJPIRKICOISLKN-WHFBIAKZSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102100024364 Disintegrin and metalloproteinase domain-containing protein 8 Human genes 0.000 claims 1
- 101710116123 Disintegrin and metalloproteinase domain-containing protein 8 Proteins 0.000 claims 1
- 102100024361 Disintegrin and metalloproteinase domain-containing protein 9 Human genes 0.000 claims 1
- 101710116121 Disintegrin and metalloproteinase domain-containing protein 9 Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 102100038437 Sodium-dependent phosphate transport protein 2B Human genes 0.000 claims 1
- 108050003877 Sodium-dependent phosphate transport protein 2B Proteins 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- CFDVGUXRLQWLJX-QGTNPELVSA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO CFDVGUXRLQWLJX-QGTNPELVSA-N 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000001601 sodium adipate Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555110P | 2017-09-07 | 2017-09-07 | |
| US62/555,110 | 2017-09-07 | ||
| US201762566824P | 2017-10-02 | 2017-10-02 | |
| US62/566,824 | 2017-10-02 | ||
| JP2020513796A JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Division JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021098733A JP2021098733A (ja) | 2021-07-01 |
| JP2021098733A5 true JP2021098733A5 (enExample) | 2021-10-14 |
Family
ID=65634405
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
| JP2021037490A Pending JP2021098733A (ja) | 2017-09-07 | 2021-03-09 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513796A Active JP7431392B2 (ja) | 2017-09-07 | 2018-09-07 | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132099A Pending JP2023166409A (ja) | 2017-09-07 | 2023-08-14 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
| JP2025026082A Pending JP2025093943A (ja) | 2017-09-07 | 2025-02-20 | Ｎｋｇ２ｄ、ｃｄ１６および腫瘍関連抗原に結合するタンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20200277383A1 (enExample) |
| EP (2) | EP3679071A4 (enExample) |
| JP (4) | JP7431392B2 (enExample) |
| KR (3) | KR20240167101A (enExample) |
| CN (3) | CN113004417A (enExample) |
| AU (3) | AU2018329937B2 (enExample) |
| BR (1) | BR112020004489A2 (enExample) |
| CA (2) | CA3112984A1 (enExample) |
| IL (2) | IL273067A (enExample) |
| MX (2) | MX2020002626A (enExample) |
| RU (1) | RU2021110369A (enExample) |
| SG (2) | SG11202001930QA (enExample) |
| WO (1) | WO2019051308A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3000558T3 (en) | 2016-08-10 | 2025-02-28 | Univ Ajou Ind Academic Coop Found | Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| AU2019366956B2 (en) | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| US20220402998A1 (en) * | 2019-10-30 | 2022-12-22 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
| IL297495A (en) * | 2020-04-22 | 2022-12-01 | Dragonfly Therapeutics Inc | Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| CA3194339A1 (en) * | 2020-09-17 | 2022-03-24 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN113563474B (zh) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | EpCAM-CD16-NKG2D三特异性抗体及其应用 |
| MX2024002187A (es) * | 2021-08-20 | 2024-03-12 | Tallac Therapeutics Inc | Anticuerpos y conjugados de nectina-4. |
| MX2024003993A (es) * | 2021-09-29 | 2024-04-25 | Dragonfly Therapeutics Inc | Proteinas que se unen al miembro d del grupo 2 de asesinos naturales (nkg2d), cumulo de diferenciacion 16(cd16) y receptor del factor activador de celulas b (baff-r). |
| KR20230060546A (ko) * | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| JP2025526346A (ja) * | 2022-07-25 | 2025-08-13 | アジェンシス，インコーポレイテッド | １９１ｐ４ｄ１２タンパク質と結合する抗体薬物複合体（ａｄｃ）をペムブロリズマブと組み合わせて用いた、局所進行性または転移性尿路上皮癌を有する患者の治療のための方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266014A2 (en) * | 2000-03-24 | 2002-12-18 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| JP2003111595A (ja) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
| CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
| US20070071759A1 (en) * | 2005-06-29 | 2007-03-29 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007067992A2 (en) | 2005-12-08 | 2007-06-14 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| JP2012511305A (ja) | 2008-12-12 | 2012-05-24 | オンコセラピー・サイエンス株式会社 | 癌の治療および診断の標的遺伝子としてのネクチン−４ |
| AU2010229192A1 (en) | 2009-03-06 | 2011-09-29 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2011003780A1 (en) * | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8637642B2 (en) | 2010-09-29 | 2014-01-28 | Seattle Genetics, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
| EP2710042A2 (en) * | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| CN120365432A (zh) | 2012-11-21 | 2025-07-25 | 武汉友芝友生物制药股份有限公司 | 双特异性抗体 |
| US10047163B2 (en) * | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| DK3021869T3 (da) * | 2013-07-16 | 2020-09-21 | Hoffmann La Roche | Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| JP6510532B2 (ja) * | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| AU2014373593B2 (en) | 2013-12-23 | 2020-07-16 | Zymeworks Bc Inc. | Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
| JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
| AU2016219785B2 (en) | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| JP6985252B2 (ja) | 2015-09-09 | 2021-12-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ネクチン−４に対する特異性を有する抗体及びその使用 |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| SG11202007482WA (en) * | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| WO2022187539A1 (en) * | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| US20230416402A1 (en) * | 2022-03-03 | 2023-12-28 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 |
-
2018
- 2018-09-07 CN CN202110251101.6A patent/CN113004417A/zh active Pending
- 2018-09-07 CN CN201880071464.8A patent/CN111315782A/zh active Pending
- 2018-09-07 AU AU2018329937A patent/AU2018329937B2/en active Active
- 2018-09-07 BR BR112020004489-0A patent/BR112020004489A2/pt unknown
- 2018-09-07 KR KR1020247038586A patent/KR20240167101A/ko active Pending
- 2018-09-07 EP EP18853095.0A patent/EP3679071A4/en active Pending
- 2018-09-07 CA CA3112984A patent/CA3112984A1/en active Pending
- 2018-09-07 JP JP2020513796A patent/JP7431392B2/ja active Active
- 2018-09-07 KR KR1020207009780A patent/KR20200044957A/ko not_active Ceased
- 2018-09-07 MX MX2020002626A patent/MX2020002626A/es unknown
- 2018-09-07 WO PCT/US2018/050073 patent/WO2019051308A1/en not_active Ceased
- 2018-09-07 CA CA3074840A patent/CA3074840A1/en active Pending
- 2018-09-07 US US16/644,585 patent/US20200277383A1/en not_active Abandoned
- 2018-09-07 SG SG11202001930QA patent/SG11202001930QA/en unknown
- 2018-09-07 KR KR1020217007213A patent/KR20210030503A/ko not_active Ceased
- 2018-09-07 SG SG10202102502VA patent/SG10202102502VA/en unknown
- 2018-09-07 CN CN202411838715.4A patent/CN119735693A/zh active Pending
- 2018-09-07 RU RU2021110369A patent/RU2021110369A/ru unknown
- 2018-09-07 EP EP21164073.5A patent/EP3925976A1/en not_active Withdrawn
-
2020
- 2020-03-04 IL IL273067A patent/IL273067A/en unknown
- 2020-03-06 MX MX2021002970A patent/MX2021002970A/es unknown
-
2021
- 2021-03-02 US US17/190,155 patent/US20210292420A1/en not_active Abandoned
- 2021-03-08 IL IL281323A patent/IL281323A/en unknown
- 2021-03-09 JP JP2021037490A patent/JP2021098733A/ja active Pending
- 2021-03-09 AU AU2021201494A patent/AU2021201494A1/en not_active Abandoned
-
2023
- 2023-02-13 US US18/108,961 patent/US20230357409A1/en active Pending
- 2023-08-14 JP JP2023132099A patent/JP2023166409A/ja active Pending
-
2024
- 2024-12-11 AU AU2024278313A patent/AU2024278313A1/en active Pending
-
2025
- 2025-02-20 JP JP2025026082A patent/JP2025093943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098733A5 (enExample) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| RU2021110369A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020508997A5 (enExample) | ||
| JP2021098732A5 (enExample) | ||
| Fischer et al. | Bispecific antibodies: molecules that enable novel therapeutic strategies | |
| FI3749346T3 (fi) | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät | |
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2020521448A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2023052214A5 (enExample) | ||
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| JP2020522473A5 (enExample) | ||
| Müller et al. | Bispecific antibodies | |
| JPWO2020033702A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JPWO2019157366A5 (enExample) | ||
| JPWO2020033587A5 (enExample) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JP2015522525A5 (enExample) | ||
| JP2020507577A5 (enExample) | ||
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 |